English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

PURPOSE: The main aim of the study was to assess the hypermethylation pattern of the tumor suppressor gene RAR-β in the plasma of patients with epithelial ovarian carcinoma and to study its role in the tumorigenesis of EOC and suggest its use as a biomarker in the early diagnosis of the disease by non-invasive methods. METHODS: 72 plasma samples, 10 corresponding matched tumor tissue specimens and 10 non-cancerous plasma samples were assessed for the aberrant hypermethylation of RAR-β by nested and MSP. STATISTICAL ANALYSIS: The data was analyzed by Fischer test and Chi Square test. The analysis for the study was performed using SPSS software version 21.0 and a p-value <0.05 was considered significant. RESULTS: Of the 72 plasma samples included in the study 17 samples showed aberrant hypermethylation of RAR-β promoter corresponding to a methylation frequency of 23.61%. Benign sample group in comparison to malignant and low malignant potential tumor groups showed a higher methylation percentage of 33.33% suggesting that hypermethylation may be an early event in ovarian cancer progression.

A STUDY ON THE ABERRANT PROMOTER HYPERMETHYLATION OF RAR - β GENE IN THE PLASMA OF EPITHELIAL OVARIAN CARCINOMA PATIENTS